Answers are grounded in this paper and cite their sources.
Hyperphosphatemia is a common complication in patients with kidney failure, despite the use of phosphate binders. Vitamin B3, either in the form of niacin or niacinamide (NAM), shows potential as "add-on" treatment to reduce serum phosphate concentrations in this population. NAM seems to lack many of the side effects that are observed with niacin. The aim of this study was to investigate whether NAM is an effective and acceptable treatment in reducing serum phosphate concentrations in patients with kidney failure.
No takes yet. Share an insight, caveat, or question.
Schepers et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: